BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

Prosit Sole is improving upon protein and cytokine therapies against validated targets for rare diseases using its chimeric protein engineering platform. The idea is to combine desirable structural features from different protein family members to...
BioCentury | Apr 29, 2020
Distillery Therapeutics

Inhibiting endocytosis to enhance cetuximab, trastuzumab and Bavencio antitumor efficacy

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; colorectal cancer; skin cancer Blocking endocytosis with DMN inhibitors could enhance the efficacy of cetuximab, trastuzumab and Bavencio avelumab against skin, breast and colorectal cancers. The mAbs target EGFR,...
BioCentury | Apr 2, 2020
Finance

Dynacure taps U.S. crossovers in €50M series C to fund orphan muscle disease studies

...investor Kurma Partners and Pontifax. The French biotech is developing antisense oligonucleotide DSN101, which modulates DNM2...
...X-linked form, which is associated with MTM1 mutations, and its autosomal dominant form, tied to DNM2...
...Bridging integrator 1 DMN2 - Dynamin 2 MTM1 - Myotubularin 1 Paul Bonanos, Associate Editor DYN101, IONIS-DNM2-2.5Rx Dynacure S.A.S. Dynamin 2 (DNM2) Myotubularin...
BioCentury | Sep 10, 2019
Distillery Therapeutics

DNM1L identified as pancreatic cancer target

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Inhibiting DNM1L, a GTPase involved in mitochondrial fission, could treat pancreatic cancer. DNM1L knockdown reduced proliferation across four patient-derived pancreatic cancer cell lines with K-Ras (KRAS) mutations. In mice...
BioCentury | Apr 10, 2019
Distillery Therapeutics

Blocking the ATAD3A-DNM1L interaction for HD

DISEASE CATEGORY: Neurology INDICATION: Huntington disease (HD) Cell culture and mouse studies identified an inhibitor of ATAD3A-DNM1L interaction that could help treat HD. An in vitro assay for proteins that bind DNM1L identified ATAD3A as...
BioCentury | Dec 12, 2018
Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Cell culture and mouse studies suggest treatment with cilnidipine or inhibiting DNM1L could help treat MI. Screening of antihypertensive drugs in primary rat cardiac fibroblasts cultured under hypoxic conditions identified that...
BioCentury | Dec 11, 2018
Distillery Therapeutics

Inflammation

INDICATION: Inflammatory disease Cell culture studies suggest combined inhibition of BRD4 and HDAC could help treat type I interferon-driven diseases. In fibroblasts from patients deficient in the type I interferon regulators ISG15 or USP18, a...
BioCentury | Jul 13, 2018
Financial News

French Orphan company Dynacure raises €47M

...2016, Dynacure is developing lead program Dyn101 (IONIS-DNM2-2.5Rx), an antisense oligonucleotide targeting the mRNA of dynamin 2 (DNM2)...
BioCentury | Jul 6, 2018
Financial News

French Orphan company Dynacure raises €47M

...2016, Dynacure is developing lead program Dyn101 (IONIS-DNM2-2.5Rx), an antisense oligonucleotide targeting the mRNA of dynamin 2 (DNM2)...
...and Cellular Biology (IGBMC) in France (see "Kurma Chameleon" ). Paul Bonanos DYN101, IONIS-DNM2-2.5Rx Andera Partners Dynacure S.A.S. Kurma Partners S.A. Dynamin 2 (DNM2)...
BioCentury | Jul 6, 2018
Finance

Dynacure’s quick transfer

...at IGBMC. In November 2017, the company selected candidate Dyn101, which targets the mRNA of dynamin 2 (DNM2)...
...a partner, although van Rooijen declined to name any indications. Paul Bonanos, Assistant Editor Dynacure S.A.S. Kurma Partners S.A. Dynamin 2 (DNM2)...
Items per page:
1 - 10 of 32